Compare Cerus Corporation vs Neighborhood Diabetes
Customers evaluate the quality of Cerus Corporation's products using the following success metrics.
Overview
Cerus Corporation is 33 yrs old and is based in United States.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development.
Neighborhood Diabetes is 26 yrs old and is based in United States.
Neighborhood Diabetes is a durable medical equipment distributor specializing in direct to consumer sales of diabetes supplies, including pharmaceuticals, and support services. In June 2011, Neighborhood Diabetes was acquired by Insulet. The valuation of Neighborhood Diabetes was $63 million.
Demo Video
Leadership
Arnaud Besnard (Managing Director)
Tom Cronin (Chief Executive Officer)
Investors
LRG Capital Group, Galleon Management
Insulet
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Cerus Corporation has not claimed their profile.
Work for Cerus Corporation? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Cerus Corporation?
Claim your profile now.
Information not available because Neighborhood Diabetes has not claimed their profile.
Work for Neighborhood Diabetes? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Neighborhood Diabetes?
Claim your profile now.